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The discovery of extracellular RNA (exRNA) has shifted our understanding of the role of
RNA in complex cellular functions such as cell-to-cell communication and a variety of
pathologies. ExRNAs constitute a heterogenous group of RNAs ranging from small (such
as microRNAs) and long non-coding to coding RNAs or ribosomal RNAs. ExRNAs can
be liberated from cells in a free form or bound to proteins as well as in association with
microvesicles (MVs), exosomes, or apoptotic bodies. Their composition and quantity
depend heavily on the cellular or non-cellular component, the origin, and the RNA
species being investigated; ribosomal RNA provides the majority of exRNA and miRNAs
are predominantly associated with exosomes or MVs. Several studies showed that
ribosomal exRNA (rexRNA) constitutes a proinflammatory and prothrombotic alarmin.
It is released by various cell types upon inflammatory stimulation and by damaged cells
undergoing necrosis or apoptosis and contributes to innate immunity responses. This
exRNA has the potential to directly promote the release of cytokines such as tumor
necrosis factor factor-α (TNF-α) or interleukin-6 from immune cells, thereby leading to a
proinflammatory environment and promoting cardiovascular pathologies. The potential
role of exRNA in different pathologies of the central nervous system (CNS) has become
of increasing interest in recent years. Although various exRNA species including both
ribosomal exRNA as well as miRNAs have been associated with CNS pathologies, their
precise roles remain to be further elucidated. In this review, the different entities of exRNA
and their postulated roles in CNS pathologies including tumors, vascular pathologies
and neuroinflammatory diseases will be discussed. Furthermore, the potential role of
exRNAs as diagnostic markers for specific CNS diseases will be outlined, as well as
possible treatment strategies addressing exRNA inhibition or interference.
Keywords: extracellular RNA, extracellular vesicles, neuroinflammation, CNS pathologies, glioblastoma
multiforme, brain metastasis, cerebral occlusive diseases, multiple sclerosis
HISTORY OF exRNA
The discovery of extracellular RNA (exRNA) has shifted our understanding of the role of RNA in
complex cellular functions such as cell-to-cell communication, pathology-related biomarkers or as
“Danger-associated Molecular Pattern” (DAMP) in the innate immune system. ExRNA was first
described in 1928 when Fred Griffith observed that non-pathogenic bacteria obtained pathogenic
properties from an infectious, heat-inactivated strain which was later explained by the exchange of
nucleic acids (Griffith, 1928; Avery et al., 1944). The presence of circulating exRNA in human blood
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GRAPHICAL ABSTRACT | Proinflammatory and prothrombotic extracellular RNA (exRNA) signaling and exRNA in CNS pathologies. (A) The interaction of exRNA
with the TLR2 agonist Pam2CSK4 results in a synergistic activation of NF-κB signaling, thereby promoting inflammation. The NF-κB pathway is also induced by
binding of exRNA to the cell membrane receptor RAGE with consecutive internalization of the nucleic acid. TLR13 which is located on endosomal membranes can
also activate NF-κB signaling through interaction with exRNA. TLR3 and TLR7 constitute two more endosomal target receptors of exRNA, which then in turn activate
TRIF and IFN-α signaling, respectively. Moreover, exRNA leads to higher levels of IL-6 and TNF- α after binding to TLR8. (B) By converting the coagulation factors VII,
X, and XII into their active forms, exRNA exerts its procoagulatory function. Furthermore, increased vascular permeability occurs as a consequence of
exRNA-VEGF-complexes binding to endothelial VEGF-R2 which subsequently results in disintegration of tight junctions. (C) Various exRNAs are associated with
pathologies of the central nervous system.
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was first discovered 1944 (Mandel, 1948). These exRNAs
comprise a variety of RNA species which are found outside
of cells in which they were transcribed, ranging from small
(such as microRNAs) and long non-coding to coding RNAs
and ribosomal RNAs. Recent data suggest that different types of
exRNA may play a key role in the pathophysiology of various
diseases such as myocardial infarction, pulmonary diseases and
autoimmune disorders (Lovgren et al., 2004; Ganguly et al., 2009;
Cabrera-Fuentes et al., 2014; Biswas et al., 2015; Zimmermann-
Geller et al., 2016; Stieger et al., 2017). Current research therefore
focuses on its utilization as a diagnostic biomarker and its
role as a potential therapeutic target (Saugstad et al., 2017;
Stieger et al., 2017).
CURRENT KNOWLEDGE OF exRNA
REGULATION
Tumor cells, apoptotic cells and monocytes/macrophages can
release RNA into the extracellular space upon inflammatory
stimulation. Once secreted or liberated, rexRNAs can act as
proinflammatory or prothrombotic alarmins, thereby increasing
vascular permeability or acting as prothrombotic cofactors,
whereas various miRNAs can be taken up in vesicular form
by target cells and alter their genetic program (Fischer et al.,
2007; Kannemeier et al., 2007; Bronisz et al., 2014; Fischer
et al., 2014). In the absence of inflammation or malignant
processes the amount of exRNA in human blood plasma and cell
culture supernatants remains low (<100 ng/ml) and increases
significantly as a consequence of pathologic processes such
as ischemia, infection, apoptosis or necrosis (Fischer et al.,
2014). Recent sequencing studies have further characterized the
distinct classes of non-cellular exRNAs (Freedman et al., 2016;
Danielson et al., 2017; Mick et al., 2017; Umu et al., 2018).
The detailed analysis of these exRNAs also poses a technical
challenge in the detection, quantification and differentiation of
these heterogenous exRNAs. This review sheds light on the
characteristics of exRNAs and their potential functional role in
CNS pathologies with a focus on vascular diseases, tumor-related,
and inflammatory pathologies.
Abbreviations: AD, Alzheimer’s Disease; ADAM17, A disintegrin and
metalloproteinase domain 17; ALS, amyotrophic lateral sclerosis; AMP,
antimicrobial peptide; BBB, blood brain barrier; BMECs, brain-derived
endothelial cells; circRNA, circular ribonucleic acid; CNS, central nervous
system; CSF, cerebrospinal fluid; DC, dendritic cell; DNA, desoxyribonucleic acid;
EV, extracellular vesicle; exDNA, extracellular desoxyrubonucleic acid; exRNA,
extracellular ribonucleic acid; FBS, fetal bovine serum; FSAP, factor VII-activating
serine protease; GBM, glioblastoma multiforme; IFN-α, interferon alpha; IFN-β,
interferon beta; IL-10, interleukin-10; IL-13, interleukin-13; IL-6, interleukin-6;
LDH, lactate dehydrogenase; LGG, low-grade glioma; lncRNA, long non-coding
ribonucleic acid; MAVS, mitochondrial antiviral signaling protein; miRNA,
micro-Ribonucleic acid; mRNA, messenger ribonucleic acid; MS, multiple
sclerosis; MV, microvesicle; NF-κB, nuclear factor “kappa-light-chain-enhancer”
of activated B-cells; NTA, nanoparticle tracking analysis; PD, Parkinson’s Disease;
piRNA, Piwi-interacting ribonucleic acid; RAGE, receptor for advanced glycation
end-products; rexRNA, ribosomal extracellular ribonucleic acid; RNA, ribonucleic
acid; RNase 1, Vascular ribonuclease 1; RNP, ribonucleoprotein; rRNA, ribosomal
ribonucleic acid; RT-qPCR, reverse transcription-quantitative polymerase chain
reaction; SAH, subarachnoid hemorrhage; snoRNA, small nucleolar ribonucleic
acid; snRNA, small nuclear ribonucleic acid; TACE, tumor necrosis factor alpha
Diversity of exRNA Species
ExRNAs are a heterogenous group of ribonucleic acids, each of
which may have a different impact on the surrounding tissue,
either alone or in association with other molecules, such as RNA-
binding proteins. The various exRNA subtypes are summarized
in Table 1 (Kim et al., 2017). These RNA species vary to a
large extent in their abundance and composition, depending
both on the investigated cellular compartment as well as the
source from which they are extracted such as body fluids, cells,
tissues or organs. ExRNAs can be liberated from cells in a free
form or bound to proteins as well as in association with MV,
exosomes, or apoptotic bodies (Ganguly et al., 2009; Crescitelli
et al., 2013). The exact mechanisms of exRNA biogenesis and
their vesicular loading have been described elsewhere (Patton
et al., 2015; Abels and Breakefield, 2016; Perez-Boza et al., 2018).
Analyses of MV-associated exRNAs have shown that miRNAs
together with rexRNAs form the majority of the vesicle-associated
fraction of exRNA in human blood plasma (Crescitelli et al., 2013;
Danielson et al., 2017) In the context of cancer, increased levels
of MV-bound extracellular mRNAs have been observed in the
blood circulation of patients and in supernatants of malignant
tumor cells (Conley et al., 2017; Lazaro-Ibanez et al., 2017;
Yokoi et al., 2017).
Established Methods of exRNA
Quantification
Methods utilized to detect and quantify exRNA depend on
the source of the compounds and the experimental set-
up for analysis. Nanoparticle tracking analysis (NTA) and
VFC constitute two approaches to analyze the quantity and
converting enzyme; TAPI, tumor necrosis factor alpha processing inhibitor; TLR,
toll-like receptor; TLR13, toll-like receptor 13; TLR2, toll-like receptor 2; TLR3,
toll-like receptor 3; TLR7, toll-like receptor 7; TLR8, toll-like receptor 8; TNF-α,
tumor necrosis factor alpha; tRNA, transfer ribonucleic acid; VEGF, vascular
endothelial growth factor; VEGF-R2, vascular endothelial growth factor receptor
2; VFC, vesicle flow cytometry; ZO-2, zona-occludens 2.
TABLE 1 | Types of exRNA.
miRNA Small, non-coding RNA (21–25 nucleotides) involved in gene
regulation (He and Hannon, 2004)
mRNA Coding RNA that evolves from DNA transcription in the process of
protein biosynthesis
tRNA Small, non-coding RNA (76–90 nucleotides) that translates mRNA
sequences in proteins
rRNA Non-coding, structural component of ribosomes
snRNA Small, non-coding RNA (about 150 nucleotides) constitutes a part
of spliceosomes (Wang et al., 2017)
lncRNA Long non-coding RNA, >200 nucleotides
circRNA Small, non-coding RNA contributes to gene regulation by
suppressing miRNA function (Wang et al., 2017)
snoRNA Small, non-coding RNA (60–300 nucleotides) (Wang et al., 2017)
modifies tRNA and rRNA chemically (Wang et al., 2017)
piRNA Small, non-coding RNA (24–32 nucleotides) mainly involved in gene
regulation of germ line cells (Wang et al., 2017)
Y RNA Small non-coding RNA; components of the Ro60 ribonucleoprotein
particle, factor for initiation of chromosomal DNA replication
(Kowalski and Krude, 2015)
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size of MVs isolated from various sources. The subsequent
characterization of a particular exRNA species contained in
MVs, exosomes or apoptotic bodies can be conducted by RT-
qPCR (Biswas et al., 2015; Saugstad et al., 2017). Analyses
of the composition of exRNA are often accomplished by
bioanalysis via capillary electrophoresis and RNA sequencing
(Fischer et al., 2014; Saugstad et al., 2017). The specific reaction
of fluorescent dyes with exRNA provides another (qualitative
or semi-quantitative) detection method (Ganguly et al., 2009).
Furthermore, dynamics of exRNA-loaded MVs can be monitored
by intravital microscopy and immunohistochemistry (van der
Vos et al., 2016). In general, the broad heterogeneity of exRNAs
combined with the variable cellular fractions and carriers can
pose challenges in further analyses and interpretation.
Functional Properties of exRNA
Although several subtypes of exRNA, including miRNAs and
non-coding long RNAs as well as rexRNA, have been described
in the context of inflammatory cell signaling, the following
subchapter focuses on rexRNA as a direct/indirect extracellular
agonist in inflammatory situations.
ExRNA as DAMPs and Toll-Like Receptor Ligands
To date, only a few exRNA-dependent cell regulatory
mechanisms are known. Receptors belonging to the family
of TLR have been shown to be activated by self-exRNA, acting as
DAMPs in the immune response toward sterile inflammation or
as a result of an infectious stimulus. Ganguly et al. demonstrated
that mainly TLR7 and TLR8 play a pivotal role in the recognition
of complexes of self-exRNA and the antimicrobial peptide
LL37, thereby leading to autoimmune reactions (Ganguly et al.,
2009). LL37 is the C-terminal peptide which is proteolytically
released from the human cathelicidin protein precursor. It has
immunomodulatory properties and prevents the degradation of
exRNA and exDNA by forming complexes with (ribo)nucleic
acids. Together with exRNA, derived from necrotic cells,
LL37 activates MAVS and induces production of IFN-β to
support maturation of DC (Zhang et al., 2016). Moreover,
the exRNA-LL37 complexes are capable of activating TLR7 in
DC, subsequently triggering the secretion of IFN-α, but not
Interleukin-6 (IL-6) or Tumor necrosis factor-α (TNF-α).
The activation of TLR8 by the complex can also lead to
differentiation of myeloid DC into mature DC and the release
of IL-6 and TNF-α. As plasmacytoid and mature myeloid DC
accumulate in psoriatic lesions at different stages of the disease,
this may indicate that complex formation of exRNA and LL37
initiates the autoimmune response and ensures its preservation
(Ganguly et al., 2009). In contrast, no activation of TLR7 (and
TLR3) by exRNA alone has been observed in macrophage
cell cultures, whereas a synergistic effect of exRNA on TLR2-
activation together with its agonist Pam2CSK4 results in the
increased expression of cytokines (Noll et al., 2017). Moreover,
in the setting of myocardial ischemia, cell-free RNA has been
described to augment apoptosis of cardiac muscle cells by
activation of TLR3-Trif signaling pathways (Chen et al., 2014).
As previously described for TLR7, TLR8, and TLR13, recognition
of exRNA can be accomplished by binding to the membrane-
bound RAGE resulting in the internalization of the nucleic acids
and activation of NF-κB pathways (Kierdorf and Fritz, 2013;
Bertheloot et al., 2016).
Stimulation of Cellular Expression and Release of
TNF-α by RexRNA
The level of rexRNA and TNF-α were found to be increased
in human blood plasma during cardiac surgery in the transient
perioperative ischemic situation (Cabrera-Fuentes et al., 2014).
The same effect has been noted in ischemia/reperfusion models
in mice and in isolated rat hearts, whereby cardiomyocytes have
been identified as a major source of rexRNA and, to a smaller
extent, smooth muscle cells and myofibroblasts. Functionally,
exRNA and TNF-α act in a feed-forward loop to promote cardiac
reperfusion injury: increase in exRNA leads to an accumulation
of TNF-α via activation of TACE, and in turn, TNF-α release
will provoke an increase of exRNA as well (Cabrera-Fuentes
et al., 2014). TACE, also known as “ADAM metalloproteinase
domain 17” (ADAM17), is a metalloproteinase that not only
cleaves the cell membrane-bound TNF-α precursor but a variety
of more than 50 other cell-bound substrates, including IL-6
receptor, VEGF-receptor 2 or NOTCH (Kanzaki et al., 2016; Li
et al., 2018). Both exRNA and TNF-α subsequently induce the
expression of inflammatory factors such as iNOS and “Monocyte-
chemoattracting Protein” (MCP)-1 to amplify the extent of
inflammation (Cabrera-Fuentes et al., 2014). Furthermore,
macrophages in cell culture exposed to rexRNA have been shown
to undergo a change in cellular characteristics from a so-called
anti- (M2) to a proinflammatory (M1) phenotype, resulting in
upregulation in gene expression of inflammatory markers such
as TNF-α, iNOS, IL-1β, and IL-6 (Cabrera-Fuentes et al., 2015).
Together, these relationships are in favor of a still hypothetical
but fundamental type of rexRNA-dependent inflammatory
cascade, starting with the exposure of exRNA (as a universal
alarmin or DAMP) at any damaged or infected tissue site
in the body. The subsequent triggering of proximally located
TACE by rexRNA in a cell type specific manner (as described
for macrophage TNF-α) will result in the production of
inflammatory or other protein products, derived from proteolytic
cleavage of the corresponding substrates by TACE. Thus, the
“non-specific” alarming factor rexRNA appears to promote site-
specific cellular responses, some of which are of profound
inflammatory relevance.
Influence of RexRNA on Blood Coagulation
It has been demonstrated that certain proteolytic reactions
in the intrinsic phase of blood coagulation, termed “contact
phase activation” are promoted by polyanionic molecules such
as polysaccharides, polyphosphates and rexRNA (Nakazawa
et al., 2005; Kannemeier et al., 2007). Here, exRNA can
augment activation of the coagulation factors XII and XI by
providing a cofactor template for their proteolytic auto-activation
(Kannemeier et al., 2007). Thus, targeting rexRNA by RNase1
has been proposed as a novel antithrombotic intervention, as
was demonstrated in thrombosis models in mice. Moreover,
histidine-rich glycoprotein in plasma can bind to rexRNA (and
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also to DNA), neutralizing their prothrombotic function and
serving as a natural anticoagulant protein (Vu et al., 2015).
Another example of a rexRNA-binding proenzyme is the
FSAP, a circulating multifunctional enzymogen, which becomes
auto-activated by specific glycosaminoglycans and rexRNA that
convert single-chain FSAP into the active two-chain form.
Subsequently, active FSAP cleaves/activates several proteins
of coagulation and fibrinolysis, but also inactivates inhibitory
proteins of coagulation, thereby enhancing the net procoagulant
level of the biological system (Nakazawa et al., 2005). In
addition, following vascular injury in mice, FSAP exhibits
vascular remodeling functions by reducing neointima formation
and vascular smooth muscle cell proliferation, leading to a
decreased risk of stenosis development (Daniel et al., 2016).
Hence, exRNA potentially supports the binary function of FSAP
in coagulation and its role in inhibiting neointima proliferation
(Nakazawa et al., 2005).
Regulation of Vascular Permeability and Infection by
RexRNA
Vascular integrity and the adhesion characteristics of
inflammatory cells and bacteria can be modulated by rexRNA
as well (Fischer et al., 2007, 2012; Zakrzewicz et al., 2016). For
example, after exposure to exRNA, cultured capillary BMEC
respond with an increased permeability, mediated by VEGF.
Thus, high affinity binding of exRNA to VEGF results in
the decomposition of endothelial tight junctions and edema
formation, initiated by VEGF-receptor 2 activation (Fischer
et al., 2007). In cremaster muscle venules, rexRNA was shown
to induce leukocyte adhesion and transmigration in vivo, and,
together with the rexRNA-induced release of proinflammatory
cytokines from monocytes, a potent inflammatory response was
achieved (Fischer et al., 2012). A recent study also showed that
exRNA-containing MV from mast cells promoted an increase
in cytokine expression of endothelial cells (Elsemuller et al.,
2019). Since rexRNA can avidly bind to particular cell surface
attached eukaryotic basic proteins such as extracellular enolase,
and also to its bacterial counterpart, host-derived rexRNA serves
to promote the adhesion of streptococci to endothelial and
epithelial cells (Zakrzewicz et al., 2016). The above findings
underline the proinflammatory and vessel-damaging potential of
circulating rexRNA.
Pharmacological RexRNA Interference
The functional properties of rexRNA, particularly its
proinflammatory activities as outlined, are effectively targeted by
natural vascular ribonuclease 1 (RNase1), the identical endocrine
counterpart to the RNase1 of the exocrine pancreas and TAPI, a
TACE inhibitor (Cabrera-Fuentes et al., 2014). Vascular RNase1
is constitutively expressed and secreted by endothelial cells of
large and medium blood vessels, but also stored in endothelial
Weibel-Palade bodies, from which it can be released by moderate
stimulation in vitro and in vivo (Fischer et al., 2011). By removing
the damaging rexRNA, RNase1 can suppress the TNF-α release in
hypoxic settings and a reduction of the inflammatory response,
or it can decrease the endothelial leakage, thus serving as a
vessel- and tissue-protective factor (Fischer et al., 2007; Cabrera-
Fuentes et al., 2014). In contrast, the long-term exposure to
TNF-α or thrombin can suppress the expression and secretion
of endothelial RNase1 (Gansler et al., 2014). RNase1 has also
been associated with antimicrobial functions by inhibiting the
rexRNA-mediated pneumococcal infection of alveolar epithelial
cells (Zakrzewicz et al., 2016). Application of RNase1 has also
been discussed as an antitumoral agent; RNase1 administration
reduced tumor volume and weight, and increased the area of
necrosis in vivo in xenograft mice models (Fischer et al., 2013;
Zakrzewicz et al., 2016).
Another inflammatory target for rexRNA-induced
inflammation is TACE, the sheddase responsible for the
release of TNF-α from macrophages. Here, the TACE inhibitor
TAPI was shown to inhibit exRNA-mediated shedding of TNF-α
in mouse bone marrow-derived macrophages as well as in
different in vivo models of cardiovascular disease, including
cardiac ischemia/reperfusion injury (Cabrera-Fuentes et al.,
2014, 2015). In addition, increased adhesion of leukocytes to
endothelial cells induced by rexRNA in vivo was attenuated by
TAPI (Fischer et al., 2012).
ExRNA IN CNS PATHOLOGIES
Various exRNA species have been investigated in the context
of CNS pathologies (Table 2) using in vivo and in vitro
models, with miRNA being the most studied subtype. MiRNAs
are small, non-coding nucleic acids and consist of about 22
nucleotides. Released under various stimulatory conditions from
any cell type, predominantly in MV-bound form, they are
taken up by target cells to modulate their protein expression
profile. Together with the Argonaute family of proteins, miRNAs
provoke RNA silencing and mRNA degradation by constraining
translation, and recruitment of responsible factors leading to
mRNA decomposition (Ha and Kim, 2014). Thus, miRNAs
serve to transmit cell-to-cell communication on the basis of
rearranging the proteome of target cells.
CNS Tumors
Glioblastomas
Glioblastomas are high-grade gliomas and represent about 30%
of all brain tumors (Ricard et al., 2012). The abundance of studies
investigating the role of exRNAs, particularly miRNAs derived
by glioblastoma cells, underlines their importance as potential
biomarkers and possible therapeutic targets (Dong et al., 2014;
Akers et al., 2015; Sathyan et al., 2015; Shi et al., 2015). It has been
shown that increased levels of MV-associated miRNAs and also
mRNAs are present in the CSF of patients suffering from GBM
(Saugstad et al., 2017). In order to capture the entire repertoire
of exRNAs in GBM, a recent study has characterized the
composition of cancer-derived exRNAs in their association with
MV, exosomes, or RNPs, using minimally-biased quantitative
analysis (Wei et al., 2017). Each subfraction exhibited a specific
RNA-composition with MV-associated exRNAs being the closest
to the cellular transcriptome (Wei et al., 2017). Extracellular
small RNAs and fragmented rRNA (designated as rexRNA) were
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TABLE 2 | exRNA in CNS pathologies.
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MVs, microvesicles; CSF, cerebrospinal fluid; RNPs, ribonucleoproteins; miR, microRNA; EVs, extracellular vesicles; BBB, blood brain barrier. ∗Might be an artificial effect
due to FBS medium.
demonstrated to form the majority of exRNAs. Tumor-derived
mRNA in CSF has been shown to be preferentially entrapped in
MVs, whereas miRNAs are primarily associated with exosomes
(Wei et al., 2017). In particular, MV-associated miR-451 and
miR-21 were shown to be incorporated by murine microglial
cells in vivo and in vitro, subsequently leading to a shift in
the phenotype of these cells toward immune suppression (van
der Vos et al., 2016). It still remains to be discussed whether
the observed increase of miR-451 originates from GBM cells,
since this miRNA was also found to be derived from the
serum component of the cell culture medium (Tosar et al.,
2017). RexRNA may play a crucial role in the context of
tumor infiltration and progression as well, since under hypoxic
conditions, GBM cells release elevated levels of rexRNA in
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comparison to non-tumor cells, and after exposure to rexRNA
in vitro, the adhesion of tumor cells to the endothelium was
shown to be increased due to extensive TNF-α release originating
from tumor-infiltrating macrophages (Fischer et al., 2013).
Low-Grade Glioma
Low-Grade Gliomas represent a heterogenous group of tumors
with a low proliferation rate that originate from different glial
cells, such as astrocytes, ependymal cells and oligodendrocytes
(Louis et al., 2007). Analyses of the exRNA-loaded MVs derived
from the CSF of patients with LGG demonstrated higher amounts
of mRNA and miRNA as compared to controls (Saugstad
et al., 2017). A recent study identified six miRNAs that were
overexpressed in tumors of glial origin: miR-4443, miR-422a,
miR-494-3p, miR-502-5p, miR-520f-3p, and miR-549a (Drusco
et al., 2018). Furthermore, miR-549a and miR-502-5p expression
correlated with prognosis in patients with tumors of glial origin
(Drusco et al., 2018).
Brain Metastases
Cerebral metastases are the most common intracranial tumors,
comprising more than 50% of CNS malignancies. The most
common primary tumors which metastasize to the CNS are lung,
breast, colon, kidney and skin cancer. A recent study in a model of
metastatic breast cancer showed that cancer-derived MVs trigger
the breakdown of the BBB (Tominaga et al., 2015). Specifically,
miR-181c secreted by metastatic cells leads to BBB disruption
which in turn supports the delocalization of circulating malignant
cells into healthy brain tissue (Tominaga et al., 2015).
Vascular Pathologies
Ischemic Stroke
Ischemic stroke is the leading cause of cerebral strokes due
to an occlusion of arteries supplying the brain with blood.
A recent study utilized unbiased next-generation sequencing
and high-throughput PCR using plasma from 40 participants of
the Framingham Heart Study. They identified seven exRNAs (6
miRNAs, 1 snoRNA) that were associated with the incidence or
prevalence of stroke (Mick et al., 2017). In rat models of transient
focal cerebral ischemia the animals developed vasogenic edema
after occlusion, whereas animals that received a pretreatment
with RNase1 were protected against edema formation. Moreover,
ischemic stroke volumes significantly decreased in pretreated
animals, suggesting a neuroprotective function of RNase1
(Fischer et al., 2007). It was further demonstrated that the
formation of brain edema was promoted by reduction of the BBB
tight junction proteins claudin-5 and ZO-2 which are essential for
barrier integrity (Fischer et al., 2007; Jiao et al., 2011; Zhao et al.,
2016). Pretreatment of animals with RNase1 led to the preserved
localization of these proteins, indicative for the vessel-protective
character of the enzyme (Fischer et al., 2007).
Hemorrhagic Stroke
Subarachnoid hemorrhage is a form of intracranial bleeding into
the subarachnoid space, between the pia mater and arachnoid
mater. Inflammatory changes of the brain parenchyma in patients
and mice post-SAH have been previously described and were
accompanied by an intraparenchymal accumulation of microglia
with subsequent neuronal apoptosis (Schneider et al., 2015;
Atangana et al., 2016). Patients suffering from SAH demonstrated
elevated levels of MV- and exosome-associated miRNA and
mRNA in the CSF, underlining the proinflammatory intra- and
extracerebral milieu post-SAH (Saugstad et al., 2017).
Thrombosis in the Brain
Sinus sagittalis thrombosis is a very rare occlusive disease
of cerebral sinuses that can be caused by a variety of
factors including infections, oral contraceptives, intracranial
hypertension, coagulation disorders or neurosurgical operations
(Xu et al., 2017; Miao et al., 2018). It has been shown
that pretreatment with RNase1 significantly reduced the sinus
occlusion rate, comparable to the effect induced by heparin
application in rat sinus venous thrombosis models. The
development of perivascular edemas was also found to be
decreased in pretreated animals. Furthermore, intravenous
application of anti-VEGF-antibodies prior to occlusion led to
reduced thrombus formation and edema development in the
same way as it has been observed after RNase1 treatment
(Fischer et al., 2007).
Multiple Sclerosis
Multiple sclerosis is a demyelinating disease that leads to
chronic inflammation of the CNS, most commonly in young
adults, and is caused by both environmental and genetic factors
(Baecher-Allan et al., 2018). In a study on patients with MS,
peripheral blood mononuclear cells and circulating miR-145 were
significantly elevated (Sondergaard et al., 2013). Another study
showed that miR-648a was significantly reduced in peripheral
blood samples of patients in remission compared to healthy
individuals (Kacperska et al., 2015). Similarly, expression of miR-
let-7a, which exhibits anti-inflammatory properties by inducing
IL-10 and IL-13, has been found to be decreased in patients in
remission compared to controls (Kacperska et al., 2015). A recent
study identified a group of nine serum exosomal miRNAs (miR-
15b-5p, miR-23a-3p, miR-223-3p, miR-374a-5p, miR-30b-5p,
miR-433-3p, miR-485-3p, miR-342-3p, and miR-432-5p) that
may distinguish relapsing-remitting from progressive MS disease
(Ebrahimkhani et al., 2017).
Neurodegenerative Diseases
Neurodegenerative diseases such as AD, ALS, or PD are
associated with a progressive loss of CNS functions. Recent
studies have focused on the potential of exRNA as diagnostic
biomarkers in these diseases. Both, patients with mild cognitive
impairment as well as those with AD showed higher plasma
or serum levels of miR-92a-3p, miR-181c-5p, miR-210-3p, and
miR-125b. An increase of miR-16, miR-29a/b, miR-30b/c/e
and miR-155 could be shown in the blood of patients
suffering from PD (Margis et al., 2011; Maciotta et al., 2013;
Tan et al., 2014; Serafin et al., 2015; Caggiu et al., 2018;
Siedlecki-Wullich et al., 2019). ALS and PD have also been
associated with the upregulation of specific miRNAs in CSF and
blood, although these findings may not always be consistent
(Hosaka et al., 2019).
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Perinatal and Traumatic Brain Injury
While specific miRNAs have been directly associated with the
consequences of perinatal and traumatic brain injury such
as neuroinflammation, arrested oligodendrocyte maturation,
neuronal apoptosis and nerve regeneration, further research is
needed to elucidate the precise mechanisms of their involvement
(Kumar et al., 2017; Pan et al., 2017; Huang et al., 2018;
Cho et al., 2019).
PERSPECTIVES IN exRNA RESEARCH
ExRNAs play a key role in inflammatory and coagulatory
pathways and are involved in tumor development and
progression. Several regulatory mechanisms and signaling
pathways of exRNA have been elucidated in various CNS
pathologies. Still, the manifold consequences of the accumulation
of nucleic acids in the extracellular space as well as the
physiological roles of different exRNAs remain to be further
investigated. Vascular RNase1 as an exRNA antagonist and
TAPI as an inhibitor of TACE may serve as anti-inflammatory
and antithrombotic agents with vessel- and neuroprotective
properties. To date, the class of miRNAs remains the most
well-characterized exRNA species, although they constitute only
a fraction of the repertoire of extracellular ribonucleic acids.
It is therefore crucial to expand the focus of research toward
other exRNA species. The examination of the appearance and
localization of exRNA in response to various pathologies as well
as the assessment of the mechanisms for exRNA liberation,
regulation and function is critical for future utilization as a
diagnostic and prognostic biomarker, and as a therapeutic target.
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